5 Questions

5 Questions

Conversations with leaders and thinkers in the field.

New

Top

Community

Psychedelic reform coming soon to a ballot box near you: 5 Questions for New Approach deputy policy director Jared Moffat

Moffat discusses New Approach’s plans for the future.

Sep 25 •

Heart risks, serotonin, and fen-phen: 5 Questions for 5-HT receptor researcher Bryan Roth

Roth discusses what we know about drugs that stimulate 5-HT receptors and their effect on the heart.

Sep 18 •

Engineering non-hallucinogenic psychedelics: 5 Questions for researcher David Olson

Olson discusses the potential of psychoplastogens and the intersection of academic research and private companies in the psychedelics space.

Sep 11 •

Liability insurance for psychedelics: 5 Questions for insurance expert Leslie Nylund

Nylund discusses Baldwin Risk Partners' new liability insurance for psychedelics practitioners

Aug 28 •

“Net-zero trauma by 2070”: 5 Questions for MAPS founder Rick Doblin

Doblin discusses his vision for a world with "net-zero trauma."

Aug 21 •

Intergenerational trauma: 5 Questions for Indigenous advocate Susan Beaulieu

Beaulieu discusses some of the root causes of trauma in Indigenous communities and what she sees as potential paths toward healing.

Aug 7 •

Oregon’s first psilocybin client: 5 Questions for retired home builder Jim Carroccio

Carroccio, thought to be the first person to receive psilocybin under Oregon’s new system, discusses his psilocybin experience.

Jul 31 •

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts